Adimmune, your trusted partner to global market
We tailor our services to customers’ needs and offer solutions for various scales, phases, and timelines. We are one of the key suppliers of high-quality vaccines and biologics around the world.
View All
Support Resilient
Supply for Vaccines
We engage with the WHO Pandemic Influenza Preparedness Framework to foster the development and access to vaccines. Recognized by US FDA and the EU, we tackle health challenges by leveraging our high standards of quality.
10 Nov. 2026
Environmental Sustainability and Health Protection Adimmune’s Analytical Method Free of Toxic Chemicals Receives TFDA Approval
Adimmune Corporation (4142) announced today that the tetanus vaccine testing and analysis method independently developed by its quality control laboratory has been approved by the Taiwan Food and Drug Administration (TFDA) under the Ministry of Health and Welfare. This breakthrough replaces carbon tetrachloride, which poses environmental and carcinogenic risks, with an organic solvent that does not contain toxic chemicals. This not only protects the health of laboratory personnel and ensures operational safety but also avoids the use of ozone-depleting toxic chemicals. This concrete action puts ESG principles into practice and ensures that sustainability is fully implemented in every detail.
06 Nov. 2026
Protecting Remote Communities and Caring for Vulnerable Groups: Adimmune Donates Influenza Vaccines to the South-Link Region and Nantou County
To protect remote communities, care for vulnerable groups, and eliminate health inequalities, Adimmune donated 500 doses of influenza vaccine to remote areas in the South-Link region this year. Furthermore, to expand assistance to disadvantaged groups, Adimmune, in partnership with Enimmune, donated 400 doses of influenza vaccine for disadvantaged residents aged 19 to 49 in Nantou County. Adimmune emphasized that, guided by its commitment to corporate sustainability, it hopes to support as many people in remote areas and disadvantaged groups as possible and, through influenza vaccine donations, promote a united approach to disease prevention and work together to protect Taiwan.
14 Jul. 2026
Adimmune Showcases New Ready-to-Use Tetanus Vaccine at CPHI Southeast Asia, Expanding Regional Market Opportunities
Adimmune Corporation (TWSE: 4142) showcased its newly launched ready-to-use tetanus vaccine at CPHI (Convention on Pharmaceutical Ingredients) Southeast Asia in Bangkok. The product attracted strong interest from Southeast Asia regional pharmaceutical companies.
